Immunotherapy of experimental and human stroke with agents approved for multiple sclerosis: a systematic review.

ABSTRACT:

Background

'Thromboinflammation' describes a novel concept in stroke pathophysiology that has opened up the possibility of immunotherapeutic approaches which could become promising strategies for targeted stroke therapies in the future.

Methods

We reviewed current evidence for agents approved for multiple sclerosis in preclinical and clinical stroke studies. A systematic review was performed in accordance with the PRISMA statement, searching MEDLINE, the Cochrane Central Register of Controlled Trials, and reference lists of articles published until 16 October 2017.

Results

The review included 52 of 629 identified studies, consisting of 5 clinical and 47 preclinical trials. Most of the studies showed beneficial effects of the evaluated immunotherapeutic drugs in terms

SUBMITTER: Dreikorn M 

PROVIDER: S-EPMC5949925 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature